Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 5 - Drugs for disorders of the endocrine system
Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908)
11/2007
11/29/2007WO2007134864A1 Indole derivatives and their use as thyroid receptor ligands
11/29/2007US20070276032 Use of 8-Prenylnaringenin for Hormone Replacement Therapy
11/29/2007US20070275102 Method of affecting sleep and sleep-related behaviors
11/29/2007US20070274974 Compositions and methods for restoring immune responsiveness in patients with immunological defects
11/29/2007US20070274914 Mptens as Modifiers of the Pten/Igf Pathway and Methods of Use
11/29/2007CA2652442A1 Antitumor agent for thyroid cancer
11/29/2007CA2652061A1 Pyrimidine low molecular weight ligands for modulating hormone receptors
11/29/2007CA2651134A1 Indole derivatives and their use as thyroid receptor ligands
11/28/2007EP1859790A2 Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
11/28/2007EP1399430B1 Oxazol/ thiazol-derivatives activators of the hppar-alpha receptor
11/28/2007EP1373257B1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
11/28/2007EP1006794B1 A method for treating or preventing alzheimer's disease
11/28/2007CN101080413A Silicon compounds and their use
11/28/2007CN101077400A Preparatory Chinese medicine for treating endocrine dyscrasia
11/28/2007CN101077350A Compostion and method of treating gonad dysfunction
11/28/2007CN100351253C Pyrrolo [2,3-d] pyrimidine compounds as immunosuppressive agents
11/28/2007CN100351250C Nobel compounds having selective inhibiting effect at GSK3
11/28/2007CN100351244C Bis-aromatic alkanols
11/27/2007US7300941 Non-imidazole compounds
11/27/2007US7300935 Gonadotropin-releasing hormone antagonistic activity, therapy of prostatic cancer, endometriosis, precocious puberty; N-(4-(1-(2,6-difluorobenzyl)-5-(((2-ethoxyethyl)(methyl)amino)methyl)-2,4-dioxo-3-(2-pyridinyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea
11/27/2007US7300933 Diazabicyclic biaryl derivatives
11/27/2007US7300927 Method for treating or preventing Alzheimer's disease
11/27/2007US7300926 Bioavailability; prevention therapy of osteoporosis ; menopause therapy; side effect reduction
11/27/2007US7300925 treating psoriasis with e.g. 19-nor-2beta-ethyl-1alpha,25-dihydroxyvitamin D3
11/27/2007US7300664 Vaginally administrable progesterone-containing tablets and method for preparing same
11/27/2007CA2271683C Coated particles, methods of making and using
11/22/2007WO2007133108A1 Pharmaceutical composition, method for the production and the use thereof
11/22/2007WO2007132179A2 Therapeutics comprising pyridinium derivatives
11/22/2007WO2007131737A2 Medication against breast cancer and related diseases
11/22/2007WO2007131736A2 Use of 4, 17 beta-dihydroxyandrost-4-ene-3-one for treating cancers
11/22/2007WO2007131286A1 Nanostructures suitable for delivery of agents
11/22/2007WO2007065023A3 Processes for obtaining lignan extracts and compositions containing the lignan extracts
11/22/2007US20070270491 Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
11/22/2007US20070270490 Use of (-)(3-trihalomethylphenoxy)(4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
11/22/2007US20070270453 TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF
11/22/2007US20070270445 Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors
11/22/2007US20070269538 Method for accelerating secretion of estrogen and regenerating tissue cells of female sexual organs
11/22/2007US20070269451 Nucleic Acid Vaccination
11/22/2007CA2652057A1 Medication against breast cancer and related diseases
11/22/2007CA2651354A1 Use of 4,17.beta.-dihydroxyandrost-4-ene-3-one for treating cancers
11/22/2007CA2638868A1 Selective vpac2 receptor peptide agonists
11/21/2007EP1857554A1 Monoclonal and chimeric antibodies specific for human tumor necrosis factor
11/21/2007EP1857553A1 Monoclonal and chimeric antibodies specific for human tumor necrosis factor
11/21/2007EP1857551A2 Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
11/21/2007EP1857115A2 Using neural thread proteins to treat tumors and other conditions requiring the removal or destruction of cells
11/21/2007EP1857110A2 Hormone replacement therapy
11/21/2007EP1623711B1 External patch containing estrogen and/or progestogen
11/21/2007EP1474139B1 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
11/21/2007EP1315515B1 Method for treating schizophrenia and related psychoses, and the use of erythropoietin or erythropoietin derivatives for treating schizophrenic disorders and related psychoses
11/21/2007EP0871463B2 Regulation of eating behavior
11/21/2007CN101076538A Steroids for cancer treatment
11/21/2007CN100349632C Microprojection array having beneficial agent contg coating
11/21/2007CN100349571C Transdermal therapeutic system containing testosterone and method for the production thereof
11/20/2007US7297711 Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
11/20/2007US7297698 e.g. (2R,5S)-4-(3-chloro-4-cyanophenyl)-N-(2-cyclopropylpyrimidin-5-yl)-2,5-dimethylpiperazine-1-carboxamide; antiandrogenic agent
11/20/2007US7297692 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them
11/20/2007US7297688 An oral contraceptive starter kit comprising at least two cycle packs of oral contraceptives containing an estrogen and a progestin, and having penultimate cycle with greater steroid dosage than last cycle pack dosage
11/20/2007US7297681 For use in therapy of growth metabolic disorders
11/15/2007WO2007129473A1 Bicyclic aryl derivative
11/15/2007WO2007129111A1 Diazepine derivatives as 5-ht2a antagonists
11/15/2007WO2007128492A1 Novel pharmaceutical compositions
11/15/2007WO2007128088A2 Use of n-aminoimidazole cytoprotective compounds for treating cell death and/or gsk-3 mediated diseases
11/15/2007WO2007076379A3 4,7-dihydrothieno[2,3-b]pyridine compounds and pharmaceutical compositions
11/15/2007US20070265349 Medicinal association of a biguanine and a carrier, for example metformin and arginine
11/15/2007US20070265296 Nuclear receptor binding agents
11/15/2007US20070265274 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating mutated-ret kinase associated diseases
11/15/2007US20070265263 Heterocyclic inhibitors of ERK2 and uses thereof
11/15/2007US20070265206 Cyclic Natriuretic Peptide Constructs
11/15/2007US20070265188 LDL Receptor-Related Proteins 1 and 2 and Treatment of Bone or Cartilage Conditions
11/15/2007US20070264345 liquid crystal gel containing polyoxyethylene-glyceryl-trioleate, 26.7-40.0%, propylene-glycol, 13.3-20.0%, isopropyl myristate, 5.0-35.0%, ethanol, 0.01-10.0%, benzyl alcohol, 0.5-1.5%, a hyaluronic acid salt or complex 0.01-2.00%, and purified water, 12.5-26.5%; healing cosmetics
11/15/2007CA2649882A1 Novel pharmaceutical compositions
11/14/2007EP1854483A1 Agent for control of function of antigen-presenting cell
11/14/2007EP1854482A1 Agent for control of degranulation reaction and cytokine production
11/14/2007EP1854465A1 Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers
11/14/2007EP1853262A1 Pharmaceutical composition comprising amorphous rosiglitazone
11/14/2007EP1853261A1 Selective inhibitors of human corticosteroid synthases
11/14/2007EP1409021B1 Formulation comprising fulvestrant
11/14/2007EP1212086B1 Immunological tolerance-induction agent
11/14/2007CN101072780A Novel tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators
11/14/2007CN101072551A Sustained release formulation comprising bisphosphonate
11/14/2007CN101070316A Di-aryl acid derivatives as ppar receptor ligands
11/14/2007CN100348609C Glucocorticoid receptor ligands for the treatment of metabolic disorders
11/14/2007CN100348600C Use of diazepins for preparing medicines for treating pathological conditions or diseases involving one of growth hormone release inhibiting factor receptors
11/14/2007CN100348598C Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments
11/14/2007CN100348265C Controlled release composition and method of producing the same
11/14/2007CN100348192C Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride
11/14/2007CN100348187C Climacteric health food
11/08/2007WO2007062877A3 PRODRUG ERβ-SELECTIVE SUBSTANCES, METHODS FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS
11/08/2007US20070259944 Amides such as 5-(3-Nitrophenyl)-1,3-dihydro-indol-2-one, used as antiprogesterones, contraceptives, for hormone replacement therapy during menopause and as anticarcinogenic agents
11/08/2007US20070259815 Albumin fusion proteins
11/08/2007US20070258974 Diagnostics and Therapeutics for Diseases Associated with Puromycin Sensitive Aminopeptidase Npepps (Npepps)
11/07/2007EP1852423A1 Crystal of 4(3h)-quinazolinone derivative
11/07/2007EP1850878A2 C-terminally pegylated growth hormones
11/07/2007EP1401408A4 Controlled heat induced rapid delivery of pharmaceuticals from skin depot
11/07/2007EP1263770B1 6-oxygenated steroidal estrogens with aromatic a and b rings
11/07/2007EP1161687B1 Grb7 family proteins and the insulin receptor for screening novel medicines.
11/07/2007CN101068764A 雌激素受体调节剂 Estrogen receptor modulators
11/07/2007CN101066997A Human antibodies that bind human IL-12 and methods for producing
11/07/2007CN101066439A Wind dispelling and obstruction eliminating capsule and its prepn
11/07/2007CN101066126A Health food suitable for middle aged and old women
1 ... 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 ... 290